{"filings":[{"id":677116,"accession_number":"0001104659-26-066575","cik":1974640,"company_name":"Apogee Therapeutics, Inc.","ticker":"APGE","form_type":"8-K","filed_at":"2026-05-27T10:40:32+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Apogee secures up to $1.3B non-dilutive financing from Blackstone for zumilokibart","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$100M upfront received; additional $100M upon Phase 3 enrollment, $200M on positive Phase 3 data.","Up to $400M more at FDA approval ($150M at Apogee's option); total synthetic royalty up to $800M.","Low-to-mid single digit tiered royalties for 15 years on worldwide net sales; no royalties above $8B.","Up to $500M senior corporate debt available at mutual consent with Blackstone.","Company removes cash runway guidance; combined with $1.3B current cash positions for self-sustainability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5919950660.512863,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":677076,"accession_number":"0001104659-26-066572","cik":1974640,"company_name":"Apogee Therapeutics, Inc.","ticker":"APGE","form_type":"8-K","filed_at":"2026-05-27T10:37:49+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Apogee reports positive Phase 2 Part B data for zumilokibart; mid-dose 65.9% EASI-75 vs 23.4% placebo","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: 65.9% mid-dose EASI-75 (p<0.001 vs placebo 23.4%) at 16 weeks.","Key secondary endpoints: IGA 0/1 46.0%, EASI-90 47.4%, I-NRS≥4 50.5% (all p<0.001).","Safety consistent with class; conjunctivitis rate for mid-dose 10.6% vs 15.1% low and 20.7% high.","Plans to initiate Phase 3 ADventure trials in 2H 2026; also Phase 2b asthma and Phase 2a EoE trials.","Blackstone Life Sciences strategic financing collaboration announced to fund through commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5919950660.512863,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97007,"accession_number":"0001193125-26-215683","cik":1974640,"company_name":"Apogee Therapeutics, Inc.","ticker":"APGE","form_type":"8-K","filed_at":"2026-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apogee reports Q1 loss of $74.1M; $1.3B cash; zumilokibart Phase 3 AD on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $74.1M in Q1 2026 vs. $55.3M a year ago; R&D spend $60.8M, G&A $22.0M.","Cash, equivalents and securities total $1.3B, up from $902.9M at Dec 2025, aided by $403M equity offering; runway into 2029.","APEX Part A 52-week data: 75% (3-month) and 85% (6-month) of EASI-75 responders maintained; IGA 0/1 maintained at 86% and 78%.","APEX Part B 16-week data in AD expected Q2 2026; Phase 3 AD initiation planned H2 2026.","Positive Phase 1b asthma data shared Jan 2026; asthma and EoE trial details expected later this year."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5919950660.512863,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97006,"accession_number":"0001193125-26-177288","cik":1974640,"company_name":"Apogee Therapeutics, Inc.","ticker":"APGE","form_type":"8-K","filed_at":"2026-04-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Two directors resign from Apogee board; board shrinks from 9 to 7","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrew Gottesdiener, M.D. and Peter Harwin notified Board of resignations effective May 11, 2026.","Resignations are not due to any disagreement with Company's operations, policies or practices.","Board size will be reduced from nine to seven directors effective May 11, 2026.","No replacements announced; CEO Michael Henderson remains in role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5919950660.512863,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111446,"accession_number":"0001104659-26-034579","cik":1974640,"company_name":"Apogee Therapeutics, Inc.","ticker":"APGE","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Apogee Therapeutics prices public offering of 5M shares at $70, net ~$377.4M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["5,000,000 shares offered at $70 per share; underwriters' option for 750,000 shares exercised in full.","Net proceeds expected ~$377.4M after underwriting discounts and commissions and estimated expenses.","Offering expected to close March 26, 2026; underwriters include Jefferies, TD Securities, Stifel, Guggenheim.","Shares sold under shelf registration statement (File No. 333-281503) effective August 12, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5919950660.512863,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111445,"accession_number":"0001104659-26-032950","cik":1974640,"company_name":"Apogee Therapeutics, Inc.","ticker":"APGE","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Apogee reports positive Phase 2 52-week zumilokibart data; durable maintenance with 3- and 6-month dosing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["EASI-75 maintained in 75% (3-month) and 85% (6-month) of Week 16 responders; vIGA 0/1 maintained in 86% and 78%.","Deepening of response across all endpoints over 52 weeks in the full zumilokibart-treated population.","Safety profile consistent with class; common TEAEs: noninfective conjunctivitis (13.4%), URTI (12.6%), nasopharyngitis (9.2%).","Part B 16-week induction data expected Q2 2026; Phase 3 initiation in 2H 2026; potential commercial launch in 2029."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5919950660.512863,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111444,"accession_number":"0001974640-26-000001","cik":1974640,"company_name":"Apogee Therapeutics, Inc.","ticker":"APGE","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apogee Therapeutics FY2025 net loss $255.8M; cash $902.9M; zumilokibart milestones","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $255.8M (FY2024: $182.1M); R&D expense $214.7M (FY2024: $167.9M).","Cash, equivalents and marketable securities $902.9M; runway into 2H 2028.","APEX Phase 2 Part A 52-week AD data expected March 2026; Part B 16-week data Q2 2026.","Phase 3 AD initiation planned 2H 2026; asthma and EoE trial details later in 2026.","Phase 1b head-to-head APG279 vs DUPIXENT in AD interim data anticipated 2H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5919950660.512863,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111443,"accession_number":"0001104659-26-001063","cik":1974640,"company_name":"Apogee Therapeutics, Inc.","ticker":"APGE","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Positive Phase 1b asthma data for zumilokibart; FeNO reduction 60%, durable to 32 weeks; 2026 milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Zumilokibart showed maximum mean FeNO reduction of 45 ppb (60% decrease) after single 720 mg dose; suppression durable through 16 weeks in all patients and up to 32 weeks in some.","Favorable safety profile: no Grade ≥3 TEAEs, SAEs, conjunctivitis, injection site reactions, or anti-drug antibodies; TEAEs included GERD and upper respiratory infection.","Positive trends in FEV1 and Type 2 biomarkers; further data to be presented at medical conferences.","2026 milestones: APEX Part A (AD, 52-week) data Q1; Part B (16-week) data Q2 (347 patients enrolled); Phase 3 AD start 2H 2026; APG279 vs DUPIXENT readout 2H 2026 (80 patients).","Pro forma cash $913M as of Sept 30, 2025; cash runway into 2H 2028 supports advancement to potential 2029 launch."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5919950660.512863,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128052,"accession_number":"0001193125-25-273250","cik":1974640,"company_name":"Apogee Therapeutics, Inc.","ticker":"APGE","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Apogee Q3 net loss $65M; APG333 half-life ~55 days supports quarterly dosing; cash $913M, runway into 2H 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q3 2025 net loss $65.0M vs $49.0M YoY; cash and securities $588.9M pre-offering, $913M pro forma post-$345M equity offering.","APG333 Phase 1 data: half-life ~55 days, biomarker suppression for 6 months, well tolerated up to 1000 mg; supports quarterly or better dosing for APG273 co-formulation.","APG777 readouts accelerated: Phase 1b asthma data Q1 2026; APEX Part A 52-week data Q1 2026; APEX Part B 16-week data Q2 2026; Phase 3 start 2H 2026.","APG279 (APG777+APG990) head-to-head vs DUPIXENT in AD interim readout expected 2H 2026.","Cash runway extended into 2H 2028 through Phase 3 topline data for APG777."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5919950660.512863,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128051,"accession_number":"0001104659-25-098487","cik":1974640,"company_name":"Apogee Therapeutics, Inc.","ticker":"APGE","form_type":"8-K","filed_at":"2025-10-10T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Apogee (APGE) raises $323M, updates APG777 atopic dermatitis and asthma trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 6.95M shares at $41 plus pre-funded warrants and full underwriter option exercise, net proceeds ~$323.3M.","APG777 APEX atopic dermatitis trial enrollment increased to 320 patients; Part B enrollment expected by year-end 2025.","Topline maintenance data from APEX Part A expected Q1 2026; 16-week induction data from Part B in Q2 2026.","Phase 1b asthma topline data for APG777 expected in Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5919950660.512863,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144833,"accession_number":"0000950170-25-106228","cik":1974640,"company_name":"Apogee Therapeutics, Inc.","ticker":"APGE","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apogee reports positive APG777 Phase 2 data and Q2 net loss of $66.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["APG777 APEX Part A met primary endpoint: 71.0% EASI reduction vs 33.8% placebo (p<0.001).","Cash, cash equivalents and marketable securities at $621.2M as of June 30, 2025; runway into Q1 2028.","Net loss of $66.1M for Q2 2025, up from $33.8M in Q2 2024, driven by higher R&D expenses.","Phase 2 Part B readout accelerated to mid-2026; Phase 3 plans on track for 2026.","First patient dosed in Phase 1b combination trial of APG279 vs DUPIXENT in atopic dermatitis."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5919950660.512863,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144832,"accession_number":"0001104659-25-065926","cik":1974640,"company_name":"Apogee Therapeutics, Inc.","ticker":"APGE","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Apogee: Phase 2 APG777 hits all endpoints; EASI-75 66.9% (42.5% placebo-adjusted), safety favorable","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["APEX Part A met primary endpoint: 71% mean EASI reduction vs 33.8% placebo (p<0.001).","EASI-75 achieved by 66.9% of APG777 patients vs 24.6% placebo (p<0.001); highest of any biologic in global study.","Rapid itch relief: 50.7% reduction in Itch NRS at Week 1 (p<0.01). Safety well-tolerated, no injection site reactions.","Exposure-response: top quartiles had 83-89% EASI-75; Part B testing higher dose, readout mid-2026.","52-week maintenance data expected 1H 2026; APG279 Phase 1b vs DUPIXENT dosed, readout 2H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":5919950660.512863,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163239,"accession_number":"0000950170-25-088600","cik":1974640,"company_name":"Apogee Therapeutics, Inc.","ticker":"APGE","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Apogee Therapeutics shareholders elect directors and ratify auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Class II directors: Bollinger (35.1M for, 4.3M withheld), Kiselak (39.2M for), Shah (25.8M for, 13.6M withheld).","Ratified Ernst & Young as independent auditor for FY2025 (41.2M for, 3K against).","Advisory vote on say-on-pay frequency: 39.4M voted for one year; company will hold annual say-on-pay votes going forward.","Broker non-votes of 1,795,017 on director elections and frequency vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":5919950660.512863,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163238,"accession_number":"0001104659-25-046955","cik":1974640,"company_name":"Apogee Therapeutics, Inc.","ticker":"APGE","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Apogee reports Q1 net loss $55.3M; positive APG808 Phase 1b data with 53% FeNO suppression","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $55.3M vs $32.1M YoY; cash $681.4M supports runway into Q1 2028.","Positive interim Phase 1b APG808 results: FeNO suppression 53% max, sustained 50% at 12 weeks; well tolerated.","Phase 2 APEX trial of APG777 advancing; interim Part A 16-week data expected mid-2025.","First patient dosed in Phase 1b APG777 asthma trial; readout expected 1H 2026.","APG279 (APG777+APG990) head-to-head vs DUPIXENT on track to initiate in 2025; readout 2H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5919950660.512863,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181162,"accession_number":"0001104659-25-022371","cik":1974640,"company_name":"Apogee Therapeutics, Inc.","ticker":"APGE","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Apogee Therapeutics enters manufacturing agreement with Samsung Biologics for APG777 drug substance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Master Services Agreement with Samsung Biologics for manufacture and supply of APG777 drug substance for clinical development and commercial sale if approved.","Initial Project Specific Agreement for clinical batches, process characterization/validation, and process performance qualification lots at Samsung's Incheon facility.","Minimum purchase quantities under Initial PSA; commercial supply PSA from 2029-2034 with minimum commitments; exit fee high single digit millions if not entered.","MSA terminates February 2035; Initial PSA terminates December 2034; termination rights for material breach, insolvency, force majeure.","Upon termination, Samsung to assist with technology transfer; without-cause termination results in payment for remaining product commitment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5919950660.512863,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181161,"accession_number":"0001104659-25-019467","cik":1974640,"company_name":"Apogee Therapeutics, Inc.","ticker":"APGE","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Apogee reports positive interim Phase 1 APG990 data with ~60-day half-life; 2024 net loss $182.1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["APG990 demonstrated ~60-day half-life, supporting every 3- and 6-month maintenance dosing; well tolerated up to 1,200 mg.","Combination APG279 (APG777+APG990) Phase 1b vs. DUPIXENT planned for 2025, readout expected H2 2026.","Full-year 2024 net loss $182.1M (vs. $84.0M in 2023); cash, equivalents and marketable securities $731.1M, runway into Q1 2028.","Phase 2 APEX trial for APG777 in atopic dermatitis over-enrolled Part A, Part B initiated; 16-week top-line data expected mid-2025.","R&D expenses $167.9M (up from $68.4M) driven by pipeline advancement and personnel costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5919950660.512863,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181160,"accession_number":"0001104659-25-008357","cik":1974640,"company_name":"Apogee Therapeutics, Inc.","ticker":"APGE","form_type":"8-K","filed_at":"2025-02-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Apogee doses first patient in Part B of Phase 2 APEX trial for APG777 in atopic dermatitis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Part A enrolled 123 patients (exceeded ~110 target) randomized 2:1 APG777 vs placebo; >90% power for primary endpoint.","Part A 16-week induction data expected mid-2025; maintenance data first half 2026; Part B 16-week data second half 2026.","APG777 modeled to exceed lebrikizumab exposures by ~30–40% with ~70–90% fewer maintenance injections vs current therapies.","Plans to initiate Phase 1b combo study of APG777 and APG990 (anti-OX40L) in AD in 2025 with readout in second half 2026.","Expansion plans include Phase 1b/2b asthma trials in 2025 and Phase 2 EoE trial in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5919950660.512863,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198017,"accession_number":"0001104659-24-127004","cik":1974640,"company_name":"Apogee Therapeutics, Inc.","ticker":"APGE","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Apogee doses first healthy volunteers in Phase 1 trial of TSLP antibody APG333","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["APG333 is a novel half-life extended monoclonal antibody targeting TSLP for asthma, COPD, and I&I conditions.","Phase 1 trial: double-blind, placebo-controlled, single-ascending dose in ~32 healthy volunteers across 4 cohorts.","Interim safety and pharmacokinetic data expected in second half of 2025.","Preclinical proof-of-concept achieved for APG777+APG333 combination; clinical trial planning underway in asthma and COPD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5919950660.512863,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198016,"accession_number":"0001104659-24-124279","cik":1974640,"company_name":"Apogee Therapeutics, Inc.","ticker":"APGE","form_type":"8-K","filed_at":"2024-12-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Apogee: APG808 Phase 1 shows 55-day half-life; APG777 data support annual dosing; Phase 2 topline now mid-2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["APG808 interim Phase 1: half-life ~55 days, supports every 2-3 month dosing; well-tolerated; Phase 1b in asthma expected 1H 2025.","APG777 Phase 1 12-month data: half-life 77 days, near complete pSTAT6 inhibition, supports potential annual dosing in AD.","APG777 Phase 2 Part A 16-week topline data accelerated to mid-2025 due to strong enrollment.","Preclinical PoC for APG777+APG990 combo: Phase 1b vs DUPIXENT in AD planned for 2025, data 2H 2026.","APG333 (anti-TSLP) Phase 1 start by end 2024; combo with APG777 in asthma/COPD under planning."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5919950660.512863,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198015,"accession_number":"0000950170-24-124542","cik":1974640,"company_name":"Apogee Therapeutics, Inc.","ticker":"APGE","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apogee Therapeutics Reports Q3 2024 Financial Results and Pipeline Progress","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities of $753.8M as of Sept 30, 2024, with runway into 2028.","Net loss for Q3 2024 was $49.0M, compared to $20.8M in Q3 2023.","APG777 Phase 2 Part A data expected in 2H 2025; interim Phase 1 data for APG808 in 4Q 2024.","APG333 development candidate nominated; Phase 1 planned for late 2024 or early 2025.","Jeff S. Hartness appointed as Chief Commercial Officer in September 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5919950660.512863,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198014,"accession_number":"0001104659-24-111027","cik":1974640,"company_name":"Apogee Therapeutics, Inc.","ticker":"APGE","form_type":"8-K","filed_at":"2024-10-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Apogee reports positive Phase 1 APG777 data: half-life ~75 days, sustained PD effect up to 9 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["APG777 half-life of ~75 days is about 3–5× longer than currently approved moderate-to-severe AD treatments.","Near-complete pSTAT6 inhibition and sustained TARC suppression observed up to 9 months after a single dose.","No serious adverse events; treatment-emergent AEs were mild-to-moderate and unrelated to study drug.","Phase 2 proof-of-concept data in moderate-to-severe AD expected in 2H 2025.","Company plans R&D Day on December 2, 2024 to update on APG777 and pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5919950660.512863,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214175,"accession_number":"0001104659-24-090690","cik":1974640,"company_name":"Apogee Therapeutics, Inc.","ticker":"APGE","form_type":"8-K","filed_at":"2024-08-19T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Apogee doses first healthy volunteers in Phase 1 trial of OX40L antibody APG990 for atopic dermatitis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initiated dosing in Phase 1 trial of APG990, a half-life extended OX40L antibody, enrolling ~40 healthy volunteers in 5 cohorts.","Interim safety and pharmacokinetic data from the Phase 1 trial expected in 2025.","Plans to start combination trial of APG777 (IL-13) and APG990 in 2025 for broader efficacy in atopic dermatitis.","CEO Michael Henderson: three programs advanced into clinical trials in 12 months since company's inception."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5919950660.512863,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214174,"accession_number":"0001104659-24-088029","cik":1974640,"company_name":"Apogee Therapeutics, Inc.","ticker":"APGE","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Apogee reports Q2 net loss $33.8M; cash $789.6M; APG777 Phase 2 dosing started","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 net loss $33.8M ($18.9M in Q2 2023); R&D expenses $33.2M, up from $13.9M.","Cash $789.6M as of June 30, 2024; runway into Q1 2028.","First patient dosed in APG777 Phase 2 trial; 16-week proof-of-concept data expected 2H2025.","APG808 interim Phase 1 data Q4 2024; APG990 Phase 1 trial accelerated to Q3 2024.","Added APG333 (anti-TSLP) to pipeline; entering clinic in 2025; combinations planned."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5919950660.512863,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233406,"accession_number":"0001104659-24-069619","cik":1974640,"company_name":"Apogee Therapeutics, Inc.","ticker":"APGE","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Apogee Therapeutics shareholders elect three Class I directors, ratify auditor, approve option grant","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Andrew Gottesdiener, Peter Harwin, and Michael Henderson as Class I directors with >33.8M votes for each.","Ratified Ernst & Young as independent auditor for FY 2024 with 41.56M votes for, 2,163 against.","Approved grant of options for 100,000 shares to a director with 40.43M votes for, 330,671 against.","All proposals passed with broker non-votes of 805,441 on director election and option grant."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5919950660.512863,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233405,"accession_number":"0001104659-24-065322","cik":1974640,"company_name":"Apogee Therapeutics, Inc.","ticker":"APGE","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Apogee Therapeutics appoints Lisa Bollinger, MD to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lisa Bollinger, MD elected as Class II director, effective May 28, 2024.","Bollinger brings 30+ years in drug development; most recently VP Regulatory Affairs at Merck (MRK).","She also served as VP Global Patient Safety at Amgen and 12 years at FDA.","Will serve on the Nominating and Corporate Governance Committee.","Appointment adds regulatory and safety expertise as Apogee advances two clinical programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5919950660.512863,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233404,"accession_number":"0001104659-24-061998","cik":1974640,"company_name":"Apogee Therapeutics, Inc.","ticker":"APGE","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Apogee starts Phase 2 AD trial for APG777; Phase 1 shows ~75-day half-life","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initiated dosing in Phase 2 trial of APG777 for moderate-to-severe atopic dermatitis (AD).","Phase 1 healthy volunteer data showed half-life of ~75 days and potentially best-in-class PK profile.","16-week proof-of-concept data from Part A expected in 2H 2025; dose optimization Part B also planned.","APG777 designed for less frequent dosing: 6 injections during induction vs 11 for lebrikizumab, 70-90% fewer in maintenance.","Phase 2 asthma trial expected to initiate in 2025; pipeline-in-a-product strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5919950660.512863,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233403,"accession_number":"0001104659-24-060195","cik":1974640,"company_name":"Apogee Therapeutics, Inc.","ticker":"APGE","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apogee reports Q1 net loss $32.1M, cash $816M, advances pipeline with Phase 2 start for APG777 and $483M raise","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $32.1M vs $12.5M YoY; R&D expenses $28.7M (up from $8.5M) as pipeline progresses.","Cash, equivalents and marketable securities $816.2M; runway into early 2028.","Completed upsized public offering raising $483M gross proceeds at $62.00/share.","Initiated Phase 2 trial of APG777 (IL-13) in atopic dermatitis; proof-of-concept data expected 2H 2025.","Dosed first participant in Phase 1 trial of APG808 (IL-4Rα); interim data expected 2H 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5919950660.512863,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}